Vial, a US-based, tech-enabled CRO providing next-generation clinical trial management services, announced on Sunday that it has added Marc Hoffmann, MD to the company's Advisory Board.
In the new role, Dr Hoffmann will work closely with the firm's leadership team to shape the scientific strategy of its Oncology CRO products and services.
Dr Hoffman is the medical director for Lean and Quality Improvement in the Cancer Center, Chair of the Lymphoma/Myeloma Disease Working Group, and an associate professor at the University of Kansas.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886